January 10, 2018 – The Tuberculosis Trials Consortium (TBTC) is a global leader in research and development for better tools to prevent, diagnose, and treat tuberculosis (TB). Housed within the U.S. Centers for Disease Control and Prevention (CDC), the TBTC conducts clinical research of high public health relevance and is key to strengthening domestic and global campaigns to eliminate TB. TBTC studies have produced several notable breakthroughs, including a shorter regimen for preventing TB (3HP) using isoniazid and rifapentine. The Community Research Advisors Group (CRAG) produced this briefing document to raise awareness of the TBTC’s legacy of accomplishments; highlight major advances in TB care resulting from TBTC studies; and make the case for increasing funding for TB research at CDC in line with the goals of the U.S. National Action Plan for Combatting Multidrug-Resistant Tuberculosis.
The CRAG is the community advisory board to the TBTC and works to support a robust TBTC research agenda that reflects community needs and priorities. Treatment Action Group provides administrative support to CRAG members, who act in a volunteer capacity.